Morphochem

German, late clinical stage biopharma developing oxazolidinone antibiotics for clostridium difficile infections

placeMunich, Bavaria, Germany calendar_todayFounded 1998 groups1 employees language morphochem.de

Registered entities

Innovation

3 patent families (3 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 41 times.

YearFilings
20191
20202
20211
20221

Investor mix

11 investors on record.

Investor typeCountShare
Venture capital545%
Private equity218%
Bank & private debt19%
Other / undisclosed327%
Coming soon